HY-15401

WAY 163909 (3-100 mg/kg; i.p., p.o.; once daily; 10 days) produces dose-dependent reductions in food intake and body weight gain in rodent obesity models, with significant triglyceride-lowering effects at higher chronic doses^[1].
WAY 163909 (0.1-30 mg/kg; i.p., p.o., s.c.; once daily; 21 days) exhibits atypical antipsychotic-like activity in rodent models, with selective effects on mesolimbic dopamine pathways and no extrapyramidal side effect liability up to 30 mg/kg i.p^[1].
WAY 163909 (10 mg/kg; i.p.; three time points: 15 min post-pretest, 5 h pre-test, 1 h pre-test) reduces immobility and increases swimming behavior in SD rats in the forced swim test, mirroring the profile of SSRIs^[2].
WAY 163909 (0.33-3.0 mg/kg; s.c.; single dose 30 min pre-test) selectively reduces aggressive behavior in resident rats in the resident-intruder model, with an ID₅₀ of 0.33 mg/kg s.c^[2].
WAY 163909 (10 mg/kg; i.p.; daily; 14 days) reduces noncontact penile erections in male SD rats, indicating sexual dysfunction liability at doses higher than those needed for antidepressant-like effects^[2].
WAY 163909 (0.3-3 mg/kg; i.p.; single injection; 15 minutes pre-ketamine) pretreatment at 1 mg/kg and 3 mg/kg significantly attenuates ketamine-induced hypothermia in male Swiss-Webster mice via activation of 5-HT₂C receptors, with the 1 mg/kg dose being the most effective^[3].